Protalix BioTherapeutics Inc. (NYSE AMERICAN: PLX)
$1.17
+0.0150 ( +1.30% ) 255.9K
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Market Data
Open
$1.17
Previous close
$1.15
Volume
255.9K
Market cap
$85.78M
Day range
$1.13 - $1.17
52 week range
$1.02 - $2.09
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Aug 17, 2023 |
4 | Insider transactions | 1 | Aug 17, 2023 |
4 | Insider transactions | 1 | Aug 17, 2023 |
4 | Insider transactions | 1 | Aug 17, 2023 |
8-k | 8K-related | 15 | Aug 07, 2023 |
10-q | Quarterly Reports | 55 | Aug 07, 2023 |
8-k | 8K-related | 13 | Jul 13, 2023 |